Literature DB >> 9722202

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

M Martinot-Peignoux1, N Boyer, M Pouteau, C Castelnau, N Giuily, V Duchatelle, A Aupérin, C Degott, J P Benhamou, S Erlinger, P Marcellin.   

Abstract

BACKGROUND/AIMS: The aim of this study was to determine the predictors for sustained response to alpha interferon therapy in a large population of patients with chronic hepatitis C, using multivariate analysis.
METHODS: Two hundred and ninety-six patients were included in four controlled trials of alpha interferon. Pretreatment serum HCV RNA levels were assessed by the branched DNA version 2.0 assay and HCV genotypes by the reverse hybridization assay (LiPA).
RESULTS: Sustained responses were observed in 37%, 14% and 6% of the patients with low, medium and high pretreatment serum HCV RNA levels, respectively (p<10(-4)). Sustained responses were observed in 5%, 4%, 32% and 27% of the patients with genotype 1a, 1b, 2a and 3a, respectively (p<10(-4)). The multivariate analysis showed that a non-transfusional source of HCV infection, low serum HCV RNA levels and HCV genotypes non-1 (2a or 3a) were independent factors associated with sustained response to interferon therapy.
CONCLUSION: Virological factors (low pretreatment serum HCV RNA level and HCV genotype non-1a and non-1b), when adjusted in a large population of patients, using improved technology, are the main independent predictors of sustained response to alpha interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9722202     DOI: 10.1016/s0168-8278(98)80006-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules.

Authors:  A Rossini; M Artini; M Levrero; C Almerighi; M Massari; L Biasi; E Radaeli; E Cariani
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

3.  Impact of ribavirin dose on retreatment of chronic hepatitis C patients.

Authors:  Christiane Stern; Michelle Martinot-Peignoux; Marie Pierre Ripault; Nathalie Boyer; Corinne Castelnau; Dominique Valla; Patrick Marcellin
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

4.  Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays.

Authors:  M Martinot-Peignoux; V Le Breton; S Fritsch; G Le Guludec; N Labouret; F Keller; P Marcellin
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

5.  Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study.

Authors:  A Andriulli; V Festa; G Leandro; M Rizzetto
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

6.  Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.

Authors:  Vinod K Dixit; Jayanta K Ghosh; Sangey C Lamtha; Pankaj Kaushik; Sundeep K Goyal; Manas K Behera; Neha Singh; Ashok K Jain
Journal:  J Clin Exp Hepatol       Date:  2014-06-18

7.  Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum.

Authors:  Pascale Trimoulet; Philippe Halfon; Eric Pohier; Hacène Khiri; Geneviève Chêne; Hervé Fleury
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

8.  External quality assessment program for qualitative and quantitative detection of hepatitis C virus RNA in diagnostic virology.

Authors:  Jurjen Schirm; Anton M van Loon; Elizabeth Valentine-Thon; Paul E Klapper; Jim Reid; Graham M Cleator
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 9.  New therapeutic approaches to hepatitis C virus.

Authors:  Naoya Sakamoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-05-21       Impact factor: 7.527

10.  Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C.

Authors:  Naohiko Masaki; Sugano Fukushima; Shigeki Hayashi
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.